I think most of you overlooked one important hint - JP mentioned that Acadia is more likely to use Trofinetide for other indications other than Fragile X and Neuren would still get the loyalties. This suggests to me that acacia is actively looking into using Trofinetide for other indications which could be another big revenue stream for NEU
- Forums
- ASX - By Stock
- NEU
- Moonsoon Briefing Thurs 20 April
Moonsoon Briefing Thurs 20 April, page-70
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$17.03 |
Change
0.700(4.29%) |
Mkt cap ! $2.176B |
Open | High | Low | Value | Volume |
$16.49 | $17.21 | $16.44 | $11.40M | 677.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4624 | $17.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$17.05 | 20000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4624 | 17.020 |
4 | 2910 | 16.990 |
1 | 175 | 16.960 |
2 | 2090 | 16.950 |
1 | 118 | 16.940 |
Price($) | Vol. | No. |
---|---|---|
17.050 | 20000 | 1 |
17.160 | 759 | 2 |
17.200 | 2650 | 1 |
17.210 | 2175 | 2 |
17.220 | 1500 | 1 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online